Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshop
Abstract
As part of the ADVANCE-VAC4PM project, the European Vaccine Initiative (EVI) and La Fondation pour la Recherche Scientifique (FORS) co-hosted a hybrid workshop titled "Strategies for using malaria vaccines to prevent malaria in pregnancy (MiP)". The event brought together researchers, regulators, civil society, global health experts, and policymakers to discuss the need for MiP vaccines and strategies for their development, evaluation, and implementation.
Malaria remains a major global health threat, with sub-Saharan Africa bearing the highest burden. Pregnant women (PW) are highly vulnerable, with an estimated 12.4 million affected in 2023. Beyond maternal health effects, a major cause of the MiP-related disease burden is placental malaria (PM), which can cause significant morbidity in newborns. PM risk is greatest in primigravidae and secundigravidae, as immunity develops over successive pregnancies. As existing malaria control strategies remain insufficient, MiP vaccines have the potential to complement them by eliciting immunity comparable to that seen in multigravidae. To be effective, such
Related
- Co-developing Georgia’s National Digital Health Strategy through a multistakeholder convergence workshop: An implementation case study from the WHO European Region
- Insights from a workshop on climate-resilience in health systems in Japan and Germany: strategies to counteract social isolation and heat health risks for older adults
- Strategies to prevent cross-transmission of multidrug-resistant microorganisms in intensive care units: A narrative review
- Prenatal psychological care to prevent emotional and reproductive complications in pregnancy after perinatal loss: a mixed methods study
- Co-designing maternal mental health interventions and implementation strategies under climate stress in Nigeria: a participatory workshop
BibTeX
@article{dalessio2026immunization,
title = {{Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshop}},
author = {Flavia d'Alessio and Josiane Honkpehedji and Sodiomon Sirima and Benoît Gamain and Nielsen Morten and Nicaise Ndam and Benjamin Mordmüller and Alassane Dicko and Rhanda Adechina and Ange Dossou and Jobiba Chinkhumba and Mandeep Kaur and Roch Houngnihin and D Scott Lamontagne and Clara Menendez and Adidja Amani and Tendai Mayani and Mary J Hamel and Elvira Carrió and Aicha Sayeh and Ayola Akim Adegnika},
journal = {Vaccine},
year = {2026},
month = sep,
doi = {10.1016/j.vaccine.2026.128505},
url = {https://hal.science/hal-05749069v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immunization strategies to prevent malaria in pregnancy – a multistakeholder workshop
AU - Flavia d'Alessio
AU - Josiane Honkpehedji
AU - Sodiomon Sirima
AU - Benoît Gamain
AU - Nielsen Morten
AU - Nicaise Ndam
AU - Benjamin Mordmüller
AU - Alassane Dicko
AU - Rhanda Adechina
AU - Ange Dossou
AU - Jobiba Chinkhumba
AU - Mandeep Kaur
AU - Roch Houngnihin
AU - D Scott Lamontagne
AU - Clara Menendez
AU - Adidja Amani
AU - Tendai Mayani
AU - Mary J Hamel
AU - Elvira Carrió
AU - Aicha Sayeh
AU - Ayola Akim Adegnika
PY - 2026
DA - 2026/09/14
JO - Vaccine
DO - 10.1016/j.vaccine.2026.128505
UR - https://hal.science/hal-05749069v1
AB - As part of the ADVANCE-VAC4PM project, the European Vaccine Initiative (EVI) and La Fondation pour la Recherche Scientifique (FORS) co-hosted a hybrid workshop titled "Strategies for using malaria vaccines to prevent malaria in pregnancy (MiP)". The event brought together researchers, regulators, civil society, global health experts, and policymakers to discuss the need for MiP vaccines and strategies for their development, evaluation, and implementation. Malaria remains a major global health threat, with sub-Saharan Africa bearing the highest burden. Pregnant women (PW) are highly vulnerable, with an estimated 12.4 million affected in 2023. Beyond maternal health effects, a major cause of the MiP-related disease burden is placental malaria (PM), which can cause significant morbidity in newborns. PM risk is greatest in primigravidae and secundigravidae, as immunity develops over successive pregnancies. As existing malaria control strategies remain insufficient, MiP vaccines have the potential to complement them by eliciting immunity comparable to that seen in multigravidae. To be effective, such
SN - 0264-410X
SN - 1873-2518
ER -